Hyperosmolarity important when planning cataract surgery

Article

It's important to evaluate tear osmolarity during surgical planning to ensure that pre-surgical keratometry readings are not compromised by hyperosmolarity of the ocular surface.

It's important to evaluate tear osmolarity during surgical planning to ensure that pre-surgical keratometry readings are not compromised by hyperosmolarity of the ocular surface.

That was the take-home message from the preliminary results of the TearLab Cataract Study, which were presented at the 2014 Congress of the European Society of Cataract and Refractive Surgeons (ESCRS).

The study of 67 patients found that hyperosmolar patients demonstrated a wider variation in keratometry calculations between visits relative to the normal osmolar group. In the hyperosmolar group, 16% of hyperosmolar eyes had more than 1 dioptre of change in K cylinder values between the first and second visit.

The preliminary results of this study evaluating the relationship of a hyperosmolar tear film on keratometry readings were presented by Dr Doyle Stulting, president of the Stulting Research Center, Woolfson Eye Institute, Atlanta, Georgia, USA.

The study results will be submitted for publication to the Journal of Cataract and Refractive Surgery.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.